Immunic AG | WebDisclosure

Basculer en Français

9805	Companies
196647	Keywords
127661	Articles
104550	Press releases

Home
Companies
Immunic AG

PRESS RELEASE

published on 10/31/2024 at 11:30, 1 year 3 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info

Financial Results Biotechnology Corporate Update Immunic Inc. Clinical Pipeline
BRIEF

published on 10/29/2024 at 11:35, 1 year 3 months ago

Immunic to Participate in Key Conferences Throughout November

Investors Biotechnology Clinical Trials Conférences Immunic
BRIEF

published on 10/29/2024 at 11:35, 1 year 3 months ago

Immunic participera à des conférences clés tout au long du mois de novembre

Biotechnologie Conférences Investisseurs Essais Cliniques Immunique
PRESS RELEASE

published on 10/29/2024 at 11:30, 1 year 3 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific
BRIEF

published on 10/22/2024 at 12:35, 1 year 3 months ago

Immunic Reports Positive Interim Results for Phase 3 ENSURE Program

Biotechnology Vidofludimus Calcium Phase 3 Trials Relapsing Multiple Sclerosis Interim Analysis
BRIEF

published on 10/22/2024 at 12:35, 1 year 3 months ago

Immunic annonce des résultats intermédiaires positifs pour la phase 3 du programme ENSURE

Biotechnologie Essais De Phase 3 Vidofludimus Calcique Sclérose En Plaques Récurrente Analyse Intermédiaire
PRESS RELEASE

published on 10/22/2024 at 12:30, 1 year 3 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 3 ENSURE Program
BRIEF

published on 09/18/2024 at 12:35, 1 year 4 months ago

Immunic Unveils Promising Vidofludimus Calcium Data at ECTRIMS Congress

Multiple Sclerosis Immunic Vidofludimus Calcium Neuroprotection ECTRIMS 2024
BRIEF

published on 09/18/2024 at 12:35, 1 year 4 months ago

Immunic dévoile des données prometteuses sur le vidofludimus calcique au congrès ECTRIMS

Sclérose En Plaques Neuroprotection Immunique Vidofludimus Calcique ECTRIMS 2024
PRESS RELEASE

published on 09/18/2024 at 12:30, 1 year 4 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark

Multiple Sclerosis Immunic Vidofludimus Calcium Therapeutic Potential ECTRIMS

Accesswire

Published on 02/05/2026 at 01:35, 1 hour 23 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 2 hours 58 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 4 hours 33 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 8 hours 58 minutes ago

Lithium South AGSM Update
Published on 02/04/2026 at 16:15, 10 hours 43 minutes ago

Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 20:54, 6 hours 4 minutes ago

Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 6 hours 22 minutes ago

EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 6 hours 58 minutes ago

Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 8 hours 3 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 8 hours 18 minutes ago

Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology

Les Echos

Published on 02/04/2026 at 18:04, 8 hours 54 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 8 hours 54 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 9 hours 13 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 9 hours 13 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 9 hours 13 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE